Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India

References

• Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236. doi:10.1080/22221751.2020.1719902
   PubMed Web of Science ®Google Scholar
• Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021;14(5):601–621. doi:10.1080/17512433.2021.1902303
   PubMed Web of Science ®Google Scholar
• Priyanka COP, Singh I, Patra G, Patra G. Aerosol transmission of SARS-CoV-2: the unresolved paradox. Travel Med Infect Dis. 2020;37:101869. doi:10.1016/j.tmaid.2020.101869
   PubMed Web of Science ®Google Scholar
• Habas K, Nganwuchu C, Shahzad F, et al. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther. 2020;18(12):1201–1211. doi:10.1080/14787210.2020.1797487
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• Gorbalenya AE, Baker SC, Baric RS; Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544. doi:10.1038/s41564-020-0695-z
   PubMed Web of Science ®Google Scholar
• Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–452. doi:10.1038/s41591-020-0820-9
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. World Health Organization. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-The-media-briefing-on-covid-19---11-march-2020. Accessed December 21, 2022.
   Google Scholar
• Güner R, Hasanoğlu I, Aktaş F. COVID-19: prevention and control measures in community. Turk J Med Sci. 2020;50(Si–1):571–577. doi:10.3906/sag-2004-146
   PubMed Web of Science ®Google Scholar
• Stokel-Walker C. What do we know about covid vaccines and preventing transmission? BMJ. 2022;376:o298. doi:10.1136/bmj.o298
   PubMedGoogle Scholar
• Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427–439. doi:10.1007/s12291-021-00968-z
   PubMed Web of Science ®Google Scholar
• Krishnamurthy K, Sobers N, Kumar A, et al. COVID-19 vaccine intent among health care professionals of Queen Elizabeth Hospital, Barbados. J Multidiscip Healthc. 2021;14:3309–3319. doi:10.2147/jmdh.s336952
   PubMed Web of Science ®Google Scholar
• Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973–1987. doi:10.1016/s0140-6736(20)31142-9
   PubMed Web of Science ®Google Scholar
• Al-Hatamleh MAI, Hatmal MM, Alshaer W, et al. COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: an overview and future perspectives based on polymersomes. Eur J Pharmacol. 2021;896:173930. doi:10.1016/j.ejphar.2021.173930
   PubMed Web of Science ®Google Scholar
• Azim Majumder MA, Razzaque MS. Repeated vaccination and ‘vaccine exhaustion’: relevance to the COVID-19 crisis. Expert Rev Vaccines. 2022;1–4. doi:10.1080/14760584.2022.2071705
   Web of Science ®Google Scholar
• Majumder MAA, Lutfor AB, Rabbi AMF, et al. Prevalence of COVID-19 vaccine reactogenicity among Bangladeshi physicians. FASEB Bioadv. 2022;4(6):379–390. doi:10.1096/fba.2021-00158
   PubMedGoogle Scholar
• Hatmal MM, Al-Hatamleh MAI, Olaimat AN, et al. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines. 2021;9(6). doi:10.3390/vaccines9060556
   Web of Science ®Google Scholar
• COVID19 Vaccine Tracker. World Health Organization. 11 vaccines granted Emergency Use Listing (EUL) by WHO. VIPER Group COVID19 Vaccine Tracker Team. Available from: https://covid19.trackvaccines.org/agency/who/. Accessed December 21, 2022.
   Google Scholar
• Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist. 2021;14:3459–3476. doi:10.2147/idr.s315727
   PubMed Web of Science ®Google Scholar
• Worldometer. COVID-19 Coronavirus Pandemic. Worldometer. Available from: https://www.worldometers.info/coronavirus/. Accessed December 21, 2022.
   Google Scholar
• Our World in Data. Coronavirus (COVID-19) vaccinations. our world in data. Available from: https://ourworldindata.org/covid-vaccinations. Accessed December 21, 2022.
   Google Scholar
• Holder J. Tracking coronavirus vaccinations around the world. The New York Times. Available from: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html. Accessed January 11, 2023.
   Google Scholar
• Gopakumar R, Mahesh J, Alexander B, Arya KS, John S, Kumbla S. Acceptance of COVID-19 vaccine among dental professionals: a cross-sectional study among practitioners, residents, and students. J Pharm Bioallied Sci. 2021;13(Suppl2):S985–s988. doi:10.4103/jpbs.jpbs_342_21
   PubMedGoogle Scholar
• World Health Organization. Statement for healthcare professionals: how COVID-19 vaccines are regulated for safety and effectiveness (Revised March 2022). Joint statement from the International Coalition of Medicines Regulatory Authorities and World Health Organization. World Health Organization. Available from: https://www.who.int/news/item/17-05-2022-statement-for-healthcare-professionals-how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness. Accessed December 21, 2022.
   Google Scholar
• Varsha Torgalkar PD. COVID killed droves of Indian health workers. Their families must fight for recompense. Los Angeles Times. Available from: https://www.latimes.com/world-nation/story/2022-01-18/india-covid-health-workers-compensation. Accessed December 21, 2022.
   Google Scholar
• Alam A, Majumder MAA, Haque M, et al. Disproportionate COVID-19 vaccine acceptance rate among healthcare professionals on the eve of nationwide vaccine distribution in Bangladesh. Expert Rev Vaccines. 2021;20:1167–1175. doi:10.1080/14760584.2021.1951248
   PubMed Web of Science ®Google Scholar
• Ashok N, Krishnamurthy K, Singh K, Rahman S, Majumder MAA. High COVID-19 vaccine hesitancy among healthcare workers: should such a trend require closer attention by policymakers? Cureus. 2021;13(9):e17990. doi:10.7759/cureus.17990
   PubMed Web of Science ®Google Scholar
• Kumar R, Beniwal K, Bahurupi Y, Kant R, Bairwa M. Determinants of COVID-19 vaccination willingness among health care workers: a quick online survey in India. Korean J Fam Med. 2021;42(6):445–452. doi:10.4082/kjfm.21.0071
   PubMed Web of Science ®Google Scholar
• Dara S, Sharma SK, Kumar A, et al. Awareness, attitude, and acceptability of healthcare workers about COVID-19 vaccination in Western India. Cureus. 2021;13(9):e18400. doi:10.7759/cureus.18400
   PubMedGoogle Scholar
• Centres for Diseases Control and Prevention (CDC). Understanding adverse events and side effects. Centres for Diseases Control and Prevention (CDC). Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/sideeffects/index.html. Accessed December 21, 2022.
   Google Scholar
• Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428. doi:10.3390/jcm10071428
   PubMed Web of Science ®Google Scholar
• World Health Organization. Side Effects of COVID-19 Vaccines. World Health Organization. Available from: https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines. Accessed December 21, 2022.
   Google Scholar
• Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4:39. doi:10.1038/s41541-019-0132-6
   PubMed Web of Science ®Google Scholar
• Centres for Diseases Control and Prevention (CDC). Understanding how COVID-19 vaccines work. Centres for Diseases Control and Prevention (CDC). Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Fdistributing%2Fsteps-ensure-safety.html. Accessed December 21, 2022.
   Google Scholar
• Kamal D, Thakur V, Nath N, Malhotra T, Gupta A, Batlish R. Adverse events following ChAdOx1 nCoV-19 vaccine (COVISHIELD) amongst health care workers: a prospective observational study. Med J Armed Forces India. 2021;77(Suppl2):S283–s288. doi:10.1016/j.mjafi.2021.06.014
   PubMedGoogle Scholar
• Kaur U, Ojha B, Pathak BK, et al. A prospective observational safety study on ChAdOx1 nCoV-19 Corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine. 2021;38:101038. doi:10.1016/j.eclinm.2021.101038
   PubMedGoogle Scholar
• Jayadevan R, Shenoy R, Ts A. Survey of symptoms following COVID-19 vaccination in India. medRxiv. 2021. doi:10.1101/2021.02.08.21251366
   Google Scholar
• Inbaraj LR, George CE, Franklyn NN. How safe is Covishield (ChAdOx1nCoV-19) vaccine? Experience from a tertiary care hospital in South India. medRxiv. 2021. doi:10.1101/2021.03.16.21253744
   Google Scholar
• Kaur S, Singh A, Saini S, et al. Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: a cross-sectional survey. Indian J Med Res. 2022. doi:10.4103/ijmr.ijmr_1221_21
   Web of Science ®Google Scholar
• Mahapatra S, Nagpal R, Marya CM, Taneja P, Kataria S. Adverse events occurring post-covid-19 vaccination among healthcare professionals - A mixed method study. Int Immunopharmacol. 2021;100:108136. doi:10.1016/j.intimp.2021.108136
   PubMed Web of Science ®Google Scholar
• Shrestha S, Devbhandari RP, Shrestha A, et al. Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal. J Patan Acad Health Sci. 2021;8(1):9–17. doi:10.3126/jpahs.v8i1.36242
   Google Scholar
• Gautam A, Dangol N, Bhattarai U, et al. ChAdOx1 nCoV-19 vaccine and its self-reported adverse events: a cross-sectional study from Western Nepal. J Glob Health Rep. 2021;5:e2021069. doi:10.29392/001c.25471
   Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–1993. doi:10.1016/s0140-6736(20)32466-1
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. doi:10.1016/s0140-6736(20)31604-4
   PubMed Web of Science ®Google Scholar
• Sachdev SS, Chettiankandy TJ, Adhane YB, Sardar MA, Yaduwanshi K. Survey on individual experiences after first dose of COVID-19 vaccination amongst Indian oral health care personnel. J Commun Health Manag. 2021;8(3):119–123. doi:10.18231/j.jchm.2021.027
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/s0140-6736(20)32661-1
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.s vaccine against covid-19. N Engl J Med. 2021;384(23):2187–2201. doi:10.1056/NEJMoa2101544
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960. doi:10.1001/jama.2020.15543
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–593. doi:10.1038/s41586-020-2639-4
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897. doi:10.1016/s0140-6736(20)31866-3
   PubMed Web of Science ®Google Scholar
• Kamble B, Bashar MA, Mishra CP. Incidence, pattern and severity of adverse events following immunization (AEFIs) associated with Chadox1 nCOV-19 corona virus vaccine (recombinant) among the healthcare workers of a tertiary care institute of Eastern Uttar Pradesh, India. Cureus. 2022;14(2):e21848. doi:10.7759/cureus.21848
   PubMed Web of Science ®Google Scholar
• Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939–949. doi:10.1016/s1473-3099(21)00224-3
   PubMed Web of Science ®Google Scholar
• Omeish H, Najadat A, Al-Azzam S, et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum Vaccin Immunother. 2022;18(1):1981086. doi:10.1080/21645515.2021.1981086
   PubMed Web of Science ®Google Scholar
• Kounis NG, Koniari I, de Gregorio C, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines. 2021;9(3):221. doi:10.3390/vaccines9030221
   Web of Science ®Google Scholar
• European Medicines Agency. Signal Assessment Report on Embolic and Thrombotic Events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [Recombinant])—Vaxzevria (Previously COVID-19 Vaccine AstraZeneca) (Other Viral Vaccines). European Medicines Agency; 2021.
   Google Scholar